Protagen, Scienion Ink Partnership | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Protagen today announced that Scienion will produce protein microarray batches of more than 1,000 arrays for Protagen for the clinical validation of biomarker panels.

In addition, under a strategic partnership, the two Dortmund, Germany-based firms will jointly evaluate new platforms for multiplexed analytics and co-develop new approaches up to proof-of-concept levels.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?